SAB Biotherapeutics Added to NASDAQ Biotechnology Index

Rhea-AI Summary

SAB Biotherapeutics (SABS) has been added to the NASDAQ Biotechnology Index effective December 20, 2021. This index tracks biotech and pharmaceutical firms listed on Nasdaq that meet specific criteria, including market cap. SAB, a clinical-stage biopharmaceutical company, focuses on immunotherapy development using fully-human polyclonal antibodies without human donors. The inclusion in the index may enhance visibility and liquidity for shareholders, and reflects its compliance with industry standards.

Positive

• Inclusion in the NASDAQ Biotechnology Index may increase visibility and trading volume.
• SAB's innovative platform for producing fully-human polyclonal antibodies can address serious diseases.

Negative

• None.

SIOUX FALLS, S.D., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it has been selected for addition to the NASDAQ Biotechnology Index^®, effective prior to market open on Monday, December 20, 2021.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market^® (Nasdaq^®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the NBI must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. The Index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund.

More information about the Index can be found at https://indexes.nasdaqomx.com/Index/Overview/NBI.

About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB’s versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: https://www.sabbiotherapeutics.com/ and follow @SABBantibody on Twitter.

Contacts:
Melissa Ullerich
+1 605-679-4609
mullerich@sabbiotherapeutics.com

Courtney Turiano (investors)
Stern IR
+1 212-698-8687
Courtney.Turiano@sternir.com

FAQ

What does the inclusion in the NASDAQ Biotechnology Index mean for SABS?

Being added to the NASDAQ Biotechnology Index may enhance visibility and potentially increase trading volume for SABS.

When did SAB Biotherapeutics join the NASDAQ Biotechnology Index?

SAB Biotherapeutics was added to the NASDAQ Biotechnology Index effective December 20, 2021.

What is the significance of the NASDAQ Biotechnology Index for biotechnology companies?

The NASDAQ Biotechnology Index tracks the performance of biotechnology and pharmaceutical companies, providing a benchmark for investors.

How does SAB Biotherapeutics develop its immunotherapies?

SAB Biotherapeutics develops immunotherapies using a novel platform that produces high-potency, fully-human polyclonal antibodies without the need for human donors.

What types of diseases does SAB Biotherapeutics target?

SAB Biotherapeutics targets infectious diseases, immune disorders, and cancer using its advanced immunotherapy platform.